Antipsychotic polypharmacy in psychotic disorders: A critical review of neurobiology, efficacy, tolerability and cost effectiveness

Journal of Psychopharmacology

Volumn 27, Issue 4, 2013, Pages 327-336

  Van Bennekom, Marc W H Lochmann ^a   Gijsman, Harm J ^a   Zitman, Frans G ^b  

^a Aurora   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antipsychotic polypharmacy; cost effectiveness; efficacy; psychosis; rationale; tolerability

Indexed keywords

AMISULPRIDE; AMPEROZIDE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PIPOTIAZINE; QUETIAPINE; RESERPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR; SULPIRIDE; TRIFLUOPERAZINE;

ANTIPSYCHOTIC POLYPHARMACY; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE UTILIZATION; HUMAN; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MONOTHERAPY; MORTALITY; NEUROBIOLOGY; NONHUMAN; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; NEURONS; POLYPHARMACY; PSYCHOTIC DISORDERS;

EID: 84875698939     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113477709     Document Type: Review

References (104)

1. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004 ; 161: 1-56
2. Anil Yagcioglu AE, Kivircik Akdede BB, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: Efficacy and safety. J Clin Psychiatry. 2005 ; 66: 63-72
3. Assion HJ, Reinbold H, Lemanski S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2008 ; 41: 24-28
4. Baandrup L, Sorensen J, Lublin H, et al. Association of antipsychotic polypharmacy with health service cost: A register-based cost analysis. Eur J Health Econ. 2012 ; 13: 355-363
5. Barbui C, Nosè M, Mazzi MA, et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol. 2006 ; 21: 355-362
6. Barbui C, Signoretti A, Mulè S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment?. Schizophr Bull. 2009 ; 35: 458-468
7. Barrett WW, Ellsworth RB, Clark LD, et al. Study of the differential behavioral effects of reserpine, chlorpromazine, and a combination of these drugs in chronic schizophrenic patients. Dis Nerv Syst. 1957 ; 18: 209-215
8. Broekema WJ, de Groot IW, van Harten PN. Simultaneous prescribing of atypical antipsychotics, conventional antipsychotics and anticholinergics - a European study. Pharm World Sci. 2007 ; 29: 126-130
9. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case- control study of risks versus benefits. Am J Psychiatry. 2004 ; 161: 700-706
10. Cha C, Hui G, Quing G. Evaluation of therapeutic effect with chlorpromazine and clozapine for the treatment of schizophrenia. Xinxiang Med Stud. 1999 ; 16: 311-316
11. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE Trial. Psychiatr Serv. 2006 ; 57: 1094-1101
12. Chang JS, Ahn YM, Park HJ, et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008 ; 69: 720-731
13. Chen A. Noncompliance in community psychiatry: A review of clinical interventions. Hosp Community Psychiatry. 1991 ; 42: 282-287
14. Chien CP, Cole JO. Depot phenothiazine treatment in acute psychosis: A sequential comparative clinical study. Am J Psychiatry. 1973 ; 130: 13-18
15. Chong SA, Ravichandran N, Poon LY, et al. Reducing polypharmacy through the introduction of a treatment algorithm: Use of a treatment algorithm on the impact on polypharmacy. Ann Acad Med Singapore. 2006 ; 35: 457-460
16. Chong SA, Remington GJ. Clozapine augmentation: Safety and efficacy. Schizophr Bull. 2000 ; 26: 421-440
17. Cipriani A, Boso M., Barbui C.. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2010 ;: CD006324
18. Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: Implications for state mental health policy. Schizophr Bull. 2002 ; 28: 75-84
19. Correll CU, Frederickson AM, Kane JM, et al. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res. 2007 ; 89: 91-100
20. Correll CU, Rummel-Kluge C, Corves C, et al. Antipsychotic combinations vs monotherapy in schizophrenia: A meta-analysis of randomized controlled trials. Schizophr Bull. 2009 ; 35: 443-457
21. Correll CU, Shaikh L, Gallego JA, et al. Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior. Schizophr Res. 2011 ; 131: 58-62
22. Di Pietro NC, Seamans JK. Dopamine and serotonin interactions in the prefrontal cortex: Insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry. 2007 ; 40: S27 - S33
23. Dougherty D, Conway PH. The '3T's' road map to transform US health care. JAMA. 2008 ; 299: 2319-2321
24. Egbe P, Engel J, Gustafsson B, et al. Amperozide and conditioned behaviour in rats: Potentiation by classical neuroleptics and alpha-methylparatyrosine. Pharmacol Toxicol. 1990 ; 66: 18-21
25. Elie D, Poirier M, Chianetta J, et al. Cognitive effects of antipsychotic dosage and polypharmacy: A study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol. 2010 ; 24: 1037-1044
26. Essock SM, Schooler NR, Stroup TS, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011 ; 168: 702-708
27. Fleischhacker W, Heikkinen ME, Olié JP, et al. Weight change on aripiprazole-clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. Eur Psychiatry. 2008 ; 23: S114 - S115
28. Fleischhacker WW, Heikkinen ME, Olie JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: A randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010 ; 13: 1115-1125
29. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002 ; 106: 323-330
30. Freudenreich O, Henderson DC, Walsh JP, et al. Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial. Schizophr Res. 2007 ; 92: 90-94
31. Friedman JI, Lindenmayer JP, Alcantara F, et al. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology. 2011 ; 36: 1289-1295
32. Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012 ; 138: 18-28
33. Ganesan S, Taylor R, Forbes I, et al. Antipsychotic polypharmacy does not increase the risk for side effects. Schizophr Res. 2008 ; 98: 323-324
34. Genc Y, Taner E., Candansayar S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized study. Adv Ther. 2007 ; 24: 1-13
35. Hazra M, Uchida H, Sproule B, et al. Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry Clin Neurosci. 2011 ; 65: 676-678
36. Higashima M, Takeda T, Nagasawa T, et al. Combined therapy with low-potency neuroleptic levomepromazine as an adjunct to haloperidol for agitated patients with acute exacerbation of schizophrenia. Eur Psychiatry. 2004 ; 19: 380-381
37. Honer WG, Procyshyn RM, Chen EY, et al. A translational research approach to poor treatment response in patients with schizophrenia: Clozapine- antipsychotic polypharmacy. J Psychiatry Neurosci. 2009 ; 34: 433-442
38. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006 ; 354: 472-482
39. Hori H, Noguchi H, Hashimoto R, et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res. 2006 ; 86: 138-146
40. Howes OD, Vergunst F, Gee S, et al. Adherence to treatment guidelines in clinical practice: Study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012 ; 201: 481-485
41. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: Psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry. 2005 ; 187: 243-247
42. Janssen B, Weinmann S, Berger M, et al. Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull. 2004 ; 30: 1023-1033
43. Jia Z, Zhang Z, Jin S. A controlled trial for comparing clozapine combined with pipothiazine palmitate to clozapine alone in the treatment of negative symptoms in schizophrenic patients. Herald Med. 2000 ; 19: 142-143
44. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005 ; 162: 130-136
45. Kapur S, Roy P, Daskalakis J, et al. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry. 2001 ; 158: 311-314
46. Kessing LV, Thomsen AF, Mogensen UB, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry. 2010 ; 197: 266-271
47. Kontis D, Theochari E, Kleisas S, et al. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010 ; 34: 1333-1341
48. Kotler M, Strous RD, Reznik I, et al. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: Evidence for improvement of mood symptomatology. Int Clin Psychopharmacol. 2004 ; 19: 23-26
49. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: A randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol. 2006 ; 21: 99-103
50. Langan J, Shajahan P. Antipsychotic polypharmacy: Review of mechanisms, mortality and management. Psychiatrist. 2010 ; 34: 58-62
51. Liu Q, Li X. A comparative study on the efficacy of combining risperidone and clozapine in the treatment of schizophrenia. Shandon Arch Psychiatry. 2001 ; 14: 28-30
52. Liu Q, Li X, Zhang Y. A control study of clozapine in combination with sulpiride in alleviating the negative symptoms of schizophrenia. Chin J Psychiatry. 1996 ; 29: 87-90
53. Matthiasson P, Erlandsson K, Costa DC, et al. Amisulpride augmentation of clozapine and striatal dopamine D2 receptor binding potential. A 123-I IBZM SPET study. Schizophr Res. 2003 ; 53: 208-209
54. Technical Report on Psychiatric Polypharmacy. Alexandria, Virginia: National Association of State Mental Health Program Directors (NASMHPD) ; 2001 :
55. Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989 ; 25: 390-392
56. Meltzer HY, Stahl SM. The dopamine hypothesis of schizophrenia: A review. Schizophr Bull. 1976 ; 2: 19-76
57. Miller AL, Craig CS. Combination antipsychotics: Pros, cons, and questions. Schizophr Bull. 2002 ; 28: 105-109
58. Misawa F, Shimizu K, Fujii Y, et al. Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A cross-sectional study. BMC Psychiatry. 2011 ; 11: 118
59. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007 ; 68: 1751-1762
60. Mossaheb N, Sacher J, Wiesegger G, et al. Haloperidol in combination with clozapine in treatment-refractory patients with schizophrenia. Eur Neuropsychopharmacol. 2006 ; 4: S416
61. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study. Schizophr Res. 2011 ; 127: 93-99
62. Schizophrenia. Full National Clinical Guideline on Core Interventions in Primary and Secondary Care. 2009 ) Schizophrenia. Full National Clinical Guideline on Core Interventions in Primary and Secondary Care (updated edition). London: The British Psychological Society & The Royal College of Psychiatrists. London: The British Psychological Society & The Royal College of Psychiatrists ; 2009 :
63. Ni J, Jang L, Hong X. Therapeutic effects of clozapine, risperidone and their combination in the treatment of schizophrenia. Heath Psychol J. 2001 ; 3: 181-182
64. Nielsen J, Emborg C, Gydesen S, et al. Augmenting clozapine with sertindole: A double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2012 ; 32: 173-178
65. Nishikawa T, Tsuda A, Tanaka M, et al. Prophylactic effects of neuroleptics in symptom-free schizophrenics: Roles of dopaminergic and noradrenergic blockers. Biol Psychiatry. 1985 ; 20: 1161-1166
66. Paton C, Whittington C, Barnes TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: A meta-analysis. J Clin Psychopharmacol. 2007 ; 27: 198-204
67. Peng H, Kuang Y, Huang X. A control study of risperidone in combination with clozapine in treating refractory schizophrenia. J Mod Clin Med Bioeng. 2001 ; 7: 100-102
68. Potter WZ, Ko GN, Zhang LD, et al. Clozapine in China: A review and preview of US/PRC collaboration. Psychopharmacology (Berl). 1989 ; 99: S87 - S91
69. Ranceva N, Ashraf W, Odelola D. Antipsychotic polypharmacy in outpatients at Birch Hill Hospital. J Clin Pharmacol. 2010 ; 50: 699-704
70. Schorr SG, Loonen AJ, Brouwers JR, et al. A cross-sectional study of prescribing patterns in chronic psychiatric patients living in sheltered housing facilities. Int J Clin Pharmacol Ther. 2008 ; 46: 146-150
71. Seeman P, Tallerico T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998 ; 3: 123-134
72. Sernyak MJ, Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry. 2004 ; 65: 1597-1600
73. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry. 1997 ; 171: 569-573
74. Shim JC, Shin JG, Kelly DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: A placebo-controlled trial. Am J Psychiatry. 2007 ; 164: 1404-1410
75. Si S, Yuan C. A comparative trial of the effects of sulpiride combined with clozapine in the treatment of chronic schizophrenia. Shandon Arch Psychiatry. 1999 ; 12: 17-20
76. Stahl SM. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?. J Clin Psychiatry. 1999 ; 60: 425-426
77. Stahl SM. Antipsychotic polypharmacy: Never say never, but never say always. Acta Psychiatr Scand. 2012 ; 125: 349-351
78. Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv. 2006 ; 57: 127-129
79. Stern RG, Schmeidler J, Davidson M. Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry. 1997 ; 42: 138-143
80. Suzuki T, Uchida H, Tanaka KF, et al. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol. 2004 ; 7: 133-142
81. Talbot DR. Are tranquilizer combinations more effective than a single tranquilizer?. Am J Psychiatry. 1964 ; 121: 597-600
82. Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand. 2009 ; 119: 419-425
83. Taylor DM, Smith L, Gee SH, et al. Augmentation of clozapine with a second antipsychotic - a meta-analysis. Acta Psychiatr Scand. 2012 ; 125: 15-24
84. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: A case note review. J Clin Psychiatry. 2003 ; 64: 30-34
85. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet. 2009 ; 9690: 620-627
86. Tranulis C, Skalli L, Lalonde P, et al. Benefits and risks of antipsychotic polypharmacy: An evidence-based review of the literature. Drug Saf. 2008 ; 31: 7-20
87. Wang J, Omori IM, Fenton M, et al. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev. 2010 ;: CD008125
88. Wang CH, Qin TE, Lin YL, et al. A clinical effect and following-up study about sulpiride and clozapine for 105 cases of the schizophrenia type. J Xinxiang Med College. 1994 ; 11: 148-151
89. Weiner E, Conley RR, Ball MP, et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology. 2010 ; 35: 2274-2283
90. Weinmann S, Aderhold V. Antipsychotic medication, mortality and neurodegeneration: The need for more selective use and lower doses. Psychosis: Psychological, Social and Integrative Approaches. 2010 ; 2: 50-69
91. Weinmann S, Hoerger S, Erath M, et al. Implementation of a schizophrenia practice guideline: Clinical results. J Clin Psychiatry. 2008 ; 69: 1299-1306
92. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: Systematic review. Schizophr Res. 2009 ; 113: 1-11
93. Wu I. A control study of risperidone and clozapine combination for treatment of refractory schizophrenia. Heath Psychol J. 2002 ; 10: 135-137
94. Xao H. A double-blind comparative study of the effects of sulpiride combined with clozapine in the treatment of schizophrenia. Sichuan Ment Health. 1999 ; 12: 250-251
95. Xie C, Ni XL. The compared study of treating schizophrenia with risperidone combining clozapine. J Prev Med Inform. 2001 ; 17: 245
96. Xin X, Du B, Zeng Z. A controlled clinical study of risperidone and low dose of clozapine in treating schizophrenia. Herald Med. 2001 ; 20: 501-502
97. Xu B. Observation of the effect of clozapine and sulpiride on negative symptom schizophrenia patients. China Tropical Medicine. 2006 ; 6: 806
98. Yagi G. A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Clin Eval. 1976 ; 3: 351-403
99. Yue H, Song L, Xu Y. A comparative trial of risperidone in the treatment of schizophrenia over two years. Shangai Arch Psychiatry. 2004 ; 16: 165-167
100. Zhang L, Xu Y. A comparison study on the treatment effect of clozapine, chlorpromazine and the combination of clozapine and chlorpromazine in schizophrenia. Chin J Nerv Ment Dis. 1989 ; 5: 306-308
101. Zhu B, Ascher-Svanum H, Faries DE, et al. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry. 2008 ; 8: 19-28
102. Zhu H, Deng D. A study of clozapine combined with or without pipothiazine palmitate in refractory schizophrenia. J Clin Psychol Med. 2002 ; 12: 15-17
103. Zhu Y, Zhang S, Zhang D. A controlled trial comparing chlorimipramine and sulpiride as adjunct to clozapine in the treatment of negative symptoms of schizophrenia. J Clin Psychol Med. 1999 ; 9: 204-205
104. Zou G, Huang Y, Zou S, et al. A comparative trial of the beneficial effects of sulpiride combined with clozapine in the treatment of refractory schizophrenia. J Yichun Univ. 2003 ; 25: 94-96